O	0	11	Feasibility
O	12	15	and
O	16	24	efficacy
O	25	27	of
O	28	29	a
B-intervention	30	36	weight
I-intervention	37	41	gain
I-intervention	42	52	prevention
O	53	65	intervention
O	66	69	for
O	70	76	breast
O	77	83	cancer
O	84	92	patients
O	93	102	receiving
O	103	114	neoadjuvant
O	115	127	chemotherapy
O	127	128	:
O	129	130	a
O	131	141	randomized
O	142	152	controlled
O	153	158	pilot
O	159	164	study
O	164	165	.

O	166	172	Weight
O	173	177	gain
O	178	180	is
O	181	187	common
O	188	193	among
O	194	200	breast
O	201	207	cancer
O	208	216	patients
O	217	220	and
O	221	224	may
O	225	235	contribute
O	236	238	to
O	239	245	poorer
O	246	255	treatment
O	256	264	outcomes
O	264	265	.

O	266	270	Most
O	271	279	programs
O	280	286	target
O	287	293	breast
O	294	300	cancer
O	301	310	survivors
O	311	316	after
O	317	320	the
O	321	331	completion
O	332	334	of
O	335	342	therapy
O	343	346	and
O	347	352	focus
O	353	355	on
O	356	362	weight
O	363	372	reduction
O	372	373	.

O	374	378	This
O	379	384	study
O	385	393	examined
O	394	397	the
O	398	409	feasibility
O	410	413	and
O	414	425	preliminary
O	426	434	efficacy
O	435	437	of
O	438	440	an
O	441	453	intervention
O	454	462	designed
O	463	465	to
O	466	473	prevent
O	474	481	primary
O	482	488	weight
O	489	493	gain
O	494	499	among
O	500	505	women
O	506	515	receiving
O	516	527	neoadjuvant
O	528	540	chemotherapy
O	541	544	for
O	545	551	breast
O	552	558	cancer
O	558	559	.

B-total-participants	560	566	Thirty
I-total-participants	566	567	-
I-total-participants	567	572	eight
B-eligibility	573	578	newly
I-eligibility	579	588	diagnosed
I-eligibility	589	594	stage
I-eligibility	595	597	II
I-eligibility	598	600	or
I-eligibility	601	604	III
I-eligibility	605	611	breast
I-eligibility	612	618	cancer
I-eligibility	619	627	patients
O	628	632	were
O	633	643	randomized
O	644	646	to
O	647	650	the
O	651	658	BALANCE
O	659	671	intervention
O	672	674	or
B-control	675	680	usual
I-control	681	685	care
O	686	692	within
O	693	694	3
O	695	700	weeks
O	701	703	of
O	704	712	starting
O	713	724	neoadjuvant
O	725	737	chemotherapy
O	737	738	.

O	739	742	The
O	743	755	intervention
O	756	760	used
O	761	762	a
O	763	767	size
O	768	778	acceptance
O	778	779	-
O	779	784	based
O	785	793	approach
O	794	797	and
O	798	808	encouraged
O	809	813	home
O	813	814	-
O	814	819	based
O	820	830	resistance
O	831	834	and
O	835	843	moderate
O	843	844	-
O	844	853	intensity
O	854	861	aerobic
O	862	870	exercise
O	871	873	as
O	874	878	well
O	879	881	as
O	882	883	a
O	884	887	low
O	888	894	energy
O	894	895	-
O	895	900	dense
O	901	905	diet
O	906	908	to
O	909	916	prevent
O	917	923	weight
O	924	928	gain
O	928	929	.

O	930	941	Assessments
O	942	946	were
O	947	956	conducted
O	957	959	at
O	960	968	baseline
O	968	969	,
O	970	973	mid
O	973	974	-
O	974	986	chemotherapy
O	987	988	(
O	988	989	3
O	990	996	months
O	996	997	)
O	997	998	,
O	999	1002	and
O	1003	1007	post
O	1007	1008	-
O	1008	1020	chemotherapy
O	1021	1022	(
O	1022	1023	6
O	1024	1030	months
O	1030	1031	)
O	1031	1032	.

O	1033	1045	Intervention
O	1046	1057	feasibility
O	1057	1058	,
O	1059	1072	acceptability
O	1072	1073	,
O	1074	1077	and
O	1078	1089	preliminary
O	1090	1097	effects
O	1098	1100	on
O	1101	1115	anthropometric
O	1115	1116	,
O	1117	1124	quality
O	1125	1127	of
O	1128	1132	life
O	1132	1133	,
O	1134	1137	and
O	1138	1149	circulating
O	1150	1159	biomarker
O	1160	1168	measures
O	1169	1173	were
O	1174	1183	evaluated
O	1183	1184	.

B-outcome	1185	1197	Intervention
I-outcome	1198	1209	participant
I-outcome	1210	1219	retention
O	1220	1221	(
O	1221	1224	100
O	1224	1225	%
O	1225	1226	)
O	1227	1230	and
B-outcome	1231	1233	in
I-outcome	1233	1234	-
I-outcome	1234	1240	person
I-outcome	1241	1248	session
I-outcome	1249	1259	attendance
O	1260	1261	(
O	1261	1263	80
O	1263	1264	%
O	1264	1265	)
O	1266	1270	were
O	1271	1275	high
O	1276	1282	during
O	1283	1286	the
O	1287	1299	intervention
O	1300	1306	period
O	1306	1307	,
O	1308	1316	although
O	1317	1327	attendance
O	1328	1335	dropped
O	1336	1338	to
O	1339	1341	43
O	1341	1342	%
O	1343	1346	for
O	1347	1356	telephone
O	1356	1357	-
O	1357	1366	delivered
O	1367	1375	sessions
O	1375	1376	.

O	1377	1380	The
O	1381	1389	majority
O	1390	1392	of
O	1393	1405	participants
O	1406	1414	reported
B-outcome	1415	1420	being
I-outcome	1421	1430	satisfied
O	1431	1435	with
O	1436	1439	the
O	1440	1452	intervention
O	1453	1459	during
O	1460	1472	chemotherapy
O	1473	1474	(
O	1474	1476	88
O	1476	1477	%
O	1477	1478	)
O	1478	1479	.

O	1480	1492	Participants
O	1493	1495	in
O	1496	1499	the
O	1500	1512	intervention
O	1513	1518	group
O	1519	1522	had
O	1523	1530	greater
B-outcome	1531	1541	reductions
I-outcome	1542	1544	in
I-outcome	1545	1550	waist
I-outcome	1551	1564	circumference
O	1565	1566	(
O	1566	1567	p
O	1568	1569	=
O	1570	1571	.
O	1571	1573	03
O	1573	1574	)
O	1575	1578	and
O	1579	1586	greater
B-outcome	1587	1599	improvements
I-outcome	1600	1602	in
I-outcome	1603	1607	self
I-outcome	1607	1608	-
I-outcome	1608	1616	reported
I-outcome	1617	1625	vitality
I-outcome	1626	1632	scores
O	1633	1634	(
O	1634	1635	p
O	1636	1637	=
O	1638	1639	.
O	1639	1641	03
O	1641	1642	)
O	1643	1647	than
O	1648	1651	the
O	1652	1659	control
O	1660	1665	group
O	1666	1668	at
O	1669	1672	the
O	1673	1676	end
O	1677	1679	of
O	1680	1692	chemotherapy
O	1692	1693	.

O	1694	1705	Significant
O	1706	1713	effects
O	1714	1716	on
O	1717	1727	biomarkers
O	1728	1732	were
O	1733	1736	not
O	1737	1745	observed
O	1745	1746	.

O	1747	1748	A
O	1749	1753	size
O	1754	1764	acceptance
O	1765	1771	weight
O	1772	1782	management
O	1783	1790	program
O	1791	1793	is
O	1794	1802	feasible
O	1803	1809	during
O	1810	1821	neoadjuvant
O	1822	1834	chemotherapy
O	1835	1840	among
O	1841	1847	breast
O	1848	1854	cancer
O	1855	1863	patients
O	1864	1867	and
O	1868	1871	may
O	1872	1876	have
O	1877	1887	beneficial
O	1888	1895	effects
O	1896	1898	on
O	1899	1904	waist
O	1905	1918	circumference
O	1919	1922	and
O	1923	1930	patient
O	1931	1939	vitality
O	1939	1940	.

O	1941	1945	This
O	1946	1951	study
O	1952	1955	was
O	1956	1966	registered
O	1967	1969	as
O	1970	1971	a
O	1972	1980	clinical
O	1981	1986	trial
O	1987	1989	at
O	1990	1993	www
O	1993	1994	.
O	1994	2008	clinicaltrials
O	2008	2009	.
O	2009	2012	gov
O	2013	2014	(
O	2014	2025	NCT00533338
O	2025	2026	)
O	2026	2027	.
